Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Humacyte Coronary Tissue Engineered Vessel (CTEV), Humacyte Coronary Tissue Engineered Vessel
CTEV · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Humacyte Coronary Tissue Engineered Vessel (CTEV) | EXPERIMENTAL | Surgically implanted CTEV for CABG |
| Name | Type | Description |
|---|---|---|
| Humacyte Coronary Tissue Engineered Vessel (CTEV) | BIOLOGICAL | The CTEV is a tissue-engineered acellular vascular conduit regulated as a biological product by the Food and Drug Administration (FDA). The CTEV has an inner diameter of 3.5 mm and with approximately 20 cm of usable length. |
Inclusion Criteria: 1. Age ≥18 years with the ability to provide written informed consent. 2. Planned first isolated CABG surgery for atherosclerotic coronary artery disease with a planned LIMA graft to the LAD and at least one other planned vessel bypass. 3. An RCA or LCx territory target vessel f...